The World Health Organization (WHO) recently prequalified the novel oral poliovirus vaccine type 2 (nOPV2), the first time the group has ever prequalified a vaccine that is being used under the emergency use listing, the Global Polio Eradication Initiative (GPEI) announced yesterday.

Rollout of the new vaccine began in March 2021, and nearly 1 billion doses have already been administered across 35 countries. WHO prequalification, though, paves the way for more countries to receive the vaccine, which has played a key role in stemming outbreaks involving type 2 variant poliovirus (cVDPV2).

The vaccine’s maker is Bio Farma Indonesia and regulators in Indonesia have fully licensed it. It was developed by an international consortium that included the Bill and Melinda Gates Foundation, the United Kingdom’s National Institute for Biological Standards and Controls (NIBSC), the U.S. Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, PATH, and the University of California at San Francisco.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.